Press release
Rising Healthcare Expenditure Driving Market Growth: A Significant Driver Propelling The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market In 2025
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
What Is the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size and Projected Growth Rate?
In recent times, the market size for chronic inflammatory demyelinating polyneuropathy (CIDP) has seen substantial growth. It's projected to expand from $2.10 billion in 2024 to $2.38 billion in 2025, experiencing a compound annual growth rate (CAGR) of 8.4%. This growth during the historic period can be linked to factors such as the rise in the elderly population, enhanced therapeutic options, heightened awareness leading to premature diagnosis, advancements in the research of immunology and autoimmune diseases, and the increasing incidence of autoimmune diseases.
The market size for chronic inflammatory demyelinating polyneuropathy (CIDP) is projected to experience solid expansion in the coming years, reaching $3.11 billion by 2029 with a compound annual growth rate (CAGR) of 8.1%. The surge in the anticipated period can be ascribed to factors such as the world's aging population, increasing emphasis on rare and autoimmune diseases, enhanced healthcare accessibility, initiatives for patient advocacy and awareness, and betterment in healthcare infrastructures. Prime trends for the predicted period encompass a rising prevalence of chronic inflammatory demyelinating polyneuropathy, progress in treatment alternatives, escalating research and development undertakings, introduction of biosimilar therapies, and the evolution of personalized medicine tactics.
Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21144
What Are the Major Segments in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?
The chronic inflammatory demyelinating polyneuropathy (CIDP) market covered in this report is segmented -
1) By Treatment: Intravenous Immunoglobulin, Corticosteroids, Plasmapheresis, Physiotherapy, Other Treatments
2) By Route Of Administration: Intravenous, Oral, Other Routes Of Administration
3) By Diagnosis: Electrodiagnostic Testing, Nerve Conduction, Electromyography (EMG), Spinal Fluid Analysis, Other Diagnosis
4) By Distribution Channel: Hospitals, Pharmacies, Online Pharmacies, Specialty Clinics
5) By End User: Hospitals, Research Institutions, Homecare Settings
Subsegments:
1) By Intravenous Immunoglobulin (IVIG): Standard IVIG Therapy, High-Dose IVIG Therapy
2) By Corticosteroids: Oral Corticosteroids, Intravenous Corticosteroids
3) By Plasmapheresis: Single-Exchange Plasmapheresis, Multiple-Exchange Plasmapheresis
4) By Physiotherapy: Muscle Strengthening Exercises, Balance And Coordination Therapy
5) By Other Treatments: Immunosuppressive Agents, Monoclonal Antibodies
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21144&type=smp
What Are The Driving Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Evolution?
The chronic inflammatory demyelinating polyneuropathy (CIDP) market is predicted to expand in the future due to the escalating costs of healthcare. This increase in healthcare expenditure is a result of heightened investments in medical facilities, a growing need for premium treatment methods, broader insurance provision, and governmental initiatives to improve healthcare availability. Greater spending in healthcare allows for more advanced treatment options, timely detection, and improved handling of CIDP, leading to enhanced patient results and life quality. For example, as reported by the Office for National Statistics, a government department based in the UK, there was a 5.6% nominal hike in the total healthcare expenses from 2022 to 2023, noted in May 2024. This increase is notably higher compared to the 0.9% growth seen in 2022. Consequently, the escalating healthcare expenditure is fueling the expansion of the chronic inflammatory demyelinating polyneuropathy (CIDP) market.
Which Firms Dominate The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Segments?
Major companies operating in the chronic inflammatory demyelinating polyneuropathy (CIDP) market are Pfizer Inc., Johnson & Johnson, Sanofi SA, Novartis AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., CSL Behring (CSL Limited), Grifols S.A., Sun Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Octapharma AG, Cipla Inc., Hikma Pharmaceuticals plc, Halozyme Therapeutics, Hualan Biological Engineering Inc, argenx SE, Hovione, Nihon Pharmaceutical Co. Ltd., Bio Products Laboratory Ltd., AdvaCare Pharma.
What Trends Are Driving Growth in The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?
The critical players in the chronic inflammatory demyelinating polyneuropathy (CIDP) market are channeling their efforts towards progressions such as intravenous immunoglobulin (IVIG) therapy to leverage treatment effectiveness and boost patient outcomes, offering more intricate and potent immune regulation for CIDP management. IVIG therapy comprises the injection of concentrated antibodies sourced from healthy contributors to regulate the immune system and diminish inflammation in autoimmune disorders. For instance, Takeda Pharmaceutical Company Limited, a biopharmaceutical firm based in Japan, disclosed FDA endorsement for GAMMAGARD LIQUID as an IVIG therapy for adult patients with CIDP in January 2024. This approval permits its application as an induction therapy, initiating with a primary dose and followed up by sustaining doses to facilitate continuous disease control and enhance neuromuscular activity.
Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/chronic-inflammatory-demyelinating-polyneuropathy-cidp-global-market-report
Which Is The Largest Region In The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?
North America was the largest region in the chronic inflammatory demyelinating polyneuropathy (CIDP) market in 2024. The regions covered in the chronic inflammatory demyelinating polyneuropathy (CIDP) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?
2. What is the CAGR expected in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?
3. What Are the Key Innovations Transforming the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Industry?
4. Which Region Is Leading the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?
Why This Report Matters:
Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.
Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.
Efficient Research: Quickly identify market growth, leading players, and major segments.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Learn More About The Business Research Company
The Business Research Company provides in-depth research and insights through a vast collection of 15,000+ reports spanning 27 industries and over 60 geographies. Backed by 1,500,000 datasets, extensive secondary research, and expert insights from industry leaders, we equip you with the knowledge needed to stay ahead in the market.
Our flagship offering, the Global Market Model, is a leading market intelligence platform that delivers comprehensive and up-to-date forecasts to support strategic decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Rising Healthcare Expenditure Driving Market Growth: A Significant Driver Propelling The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market In 2025 here
News-ID: 4069596 • Views: …
More Releases from The Business Research Company
Pesticide And Other Agricultural Chemicals Industry Set to Achieve $156.05 Billi …
Get 30% off global market reports with code ONLINE30 and keep ahead of tariffs, macro trends, and worldwide economic developments.
What Is the Long-Term Growth Forecast for the Pesticide And Other Agricultural Chemicals Market Size 2025?
In recent years, the market size for pesticides and other agricultural chemicals has witnessed significant growth. From a value of $104.46 billion in 2024, it's projected to swell to $113.13 billion in 2025, reflecting a compound…
Organophosphates Pesticides Industry Expected to Reach $10.67 Billion by 2029 at …
Stay informed on tariff shifts, macro trends, and global economic changes-use code ONLINE30 to enjoy 30% off our global market reports.
Organophosphates Pesticides Market Value Projection: How Much Will the Market Size by 2025?
The market size of organophosphates pesticides has experienced consistent growth in the prior years. The market is projected to expand from $8.05 billion in 2024 to $8.41 billion in 2025, with a compound annual growth rate (CAGR) of…
Nitrobenzene Industry Growth Outlook: 7.5% CAGR and $15.35 Billion by 2029
Get 30% off global market reports with code ONLINE30 and keep ahead of tariffs, macro trends, and worldwide economic developments.
What Is the Long-Term Growth Forecast for the Nitrobenzene Market Size 2025?
In the past few years, the size of the nitrobenzene market has witnessed significant growth. It is projected to increase from $10.96 billion in 2024 to $11.51 billion in 2025, with a compound annual growth rate (CAGR) of 5.1%. The…
Nail Polish Market Analysis: $24.61 Billion by 2029 With a CAGR of 11.5%
Stay informed on tariff shifts, macro trends, and global economic changes-use code ONLINE30 to enjoy 30% off our global market reports.
Nail Polish Market Value Projection: How Much Will the Market Size by 2025?
The industry of nail polish has witnessed significant expansion in the past few years. Projected to surge from $14.39 billion in 2024 to $15.93 billion in 2025, it is expected to observe a compound annual growth rate (CAGR)…
More Releases for CIDP
Evolving Market Trends In The Hyqvia Industry: FDA Approval For Immune Globulin …
The Hyqvia Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Hyqvia Market Size During the Forecast Period?
In recent times, the hyqvia market size has experienced a XX (HCAGR). Expectations are in place for it to escalate from $XX million in 2024…
Key Trend Reshaping the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) …
What combination of drivers is leading to accelerated growth in the chronic inflammatory demyelinating polyneuropathy (cidp) market?
The increasing healthcare expenditure is expected to propel the growth of the chronic inflammatory demyelinating polyneuropathy (CIDP) market. Rising healthcare expenditure is a result of increased investments in medical infrastructure, demand for advanced treatments, expanded insurance coverage, and efforts to improve healthcare access. This increased spending facilitates better diagnosis and management of CIDP, a…
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Market Insights and Co …
The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market sector is undergoing significant transformation, with substantial growth and technological advancements expected by 2031. According to a new in-depth market research report, the sector is poised for expansion, driven by various factors such as market size, share, and emerging trends.
This comprehensive report provides key insights into the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market, exploring critical market segmentation and definitions. It highlights the essential…
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Treatment Market 2024-2 …
Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market is an uncommon autoimmune disorder affecting the peripheral nervous system. It manifests through the progressive weakening of muscles and the loss of sensation in extremities. The CIDP treatment market has shown consistent growth and is poised for significant expansion in the forthcoming years. In this comprehensive blog post, we will delve into the current scenario, regulatory framework, market dynamics, supplier landscape, drug distribution model,…
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Market Insights …
The market for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) was valued USD 968 Million in 2017 which is anticipated to reach USD 2,020.6 Million by 2030.
The total number of CIDP patients in the 7MM is projected to reach 55,113 by 2030 from 46,027 in 2019. The U.S. has the highest incidences of CIDP in the 7MM. In 2019, as per the data studied by Report Ocean, there were approximately 29,000…
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Treatment Market Forayi …
Chronic Inflammatory Demyelinating polyneuropathy (CIDP) is a rare neurological disorder which causes paralysis (impairment of sensory function in limbs). It occurs due to the inflammation of nerve roots, peripheral nerves, and destruction of the fatty protective covering (myelin sheath) over the nerves. It slows down the transmission of nerve signals, thus leading to destruction of nerve fibers. It can be treated with corticosteroids or in combination with an immunosuppressant, plasma…
